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Abstract The prevalence of colorectal cancer is high in the western world and
follow-up after treatment of the primary tumour is claimed to consume resources
that could be used in improving screening and early diagnosis. Although some
patients with recurrent disease can be treated successfully there has been a debate
on whether an overall improvement in survival is achieved by follow-up. There is no
agreement on a follow-up protocol of investigations. A review via a Medline search
of all published studies and reports on the issue of follow-up of colorectal cancer
dated from 1975e2006. We examined retrospective and prospective studies, rando-
mised controlled trials, and meta-analyses attempting to identify the optimum
follow-up protocol. There is widespread diversity of follow-up policies for colorec-
tal cancer. Follow-up of colorectal cancer does not have a negative impact on
Quality of life. There is no evidence that annual colonoscopy provides any survival
advantage. It has been shown that intensive follow-up with frequent carcinoem-
bryonic antigen measurement has a survival advantage and is cost-efficient. Similar
evidence seems to be gathering about liver imaging with CT scan although it is less
conclusive.
ª 2006 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Background
Colorectal Cancer is the second commonest cancer
in the United Kingdom today. Its incidence is 35e
57 cases/100,000 people/year with 30,000 new
cases and 10,000 deaths every year. Local or
E-mail address: s.pap@talk21.com1743-9191/$ - see front matter ª 2006 Surgical Associates Ltd. P
doi:10.1016/j.ijsu.2006.04.004systemic recurrence of the tumour is always fatal
if left untreated.
The incidence of recurrence varies according to
the stage of the tumour on presentation as well
as other risk factors such as adverse histological
features (poor differentiation, vascular and lym-
phatic invasion, perineural invasion). The risk of
distal recurrence is less than 10% in Dukes A stage
tumours while it climbs to 50% or higher in Dukes Cublished by Elsevier Ltd. All rights reserved.
Follow-up of patients with colorectal cancer 121Table 1 Summary of studies not supporting follow-up of colorectal cancer in chronological order
Study Design Comments
Cochrane 1980 Retrospective Dated investigations & treatments examined
Hutton 1989 Non-randomised Underpowered, clinical assessment mainly
Moertel 1993 Retrospective Evaluation of CEA only
McCall 1994 Non-randomised Follow-up not long enough
Lennon 1995 RCT Dated methods (exploratory laparotomy)
Ohlson 1995 RCT CEA, Colonoscopy only, no CT liver, underpowered
Makela 1995 RCT CT liver, high proportion of Dukes A
Kjeldsen 1997 RCT No CT or CEA, inadequate investigations
Schoemaker 1998 RCT CT liver, CEA, Colonoscopy, good quality RCTtumours. Recurrence tends to be either local or
distal. Distal recurrence occurs mainly in the liver
or lungs and there is no evidence that it depends
on surgical technique. Local recurrence of rectal
cancer has been understood in depth since the
work of Heald with the introduction of the surgical
technique of Total Mesorectal Excision (TME) and
with correct application of the technique the
incidence of local recurrence should be around
5%, even in Dukes C rectal tumours.1
There has been a debate for more than twenty
years on whether there is any benefit from
follow-up after curative colorectal cancer surgery
(Table 1). Supporters of intensive follow-up
schemes argue that if recurrence of colorectal
cancer is discovered and managed earlier patients
live longer (Table 2). This happens mainly if
recurrent disease of the bowel, liver or lung is
discovered while it is still resectable with repeat
radical surgery2,3 however resection is not always
possible even among the selected cases referred
to liver surgeons for this purpose.4 Ablation ther-
apy (such as cryotherapy or radiowave frequency
ablation) is a new method of treating liver dis-
ease which might increase survival in previously
unresectable recurrence.5
The ideal combination of investigations should
have high diagnostic accuracy, be minimally in-
vasive and not affect patient’s quality of life and
also demonstrate cost-efficiency. Experience and
research shows that it is extremely difficult
for surgeons and oncologists to agree which
combination of methods fulfils better the aboverequirements. The American Society of Clinical
Oncology has defined the outcomes that justify
diagnostic tests and treatments in order to com-
bine non-invasiveness, clinical usefulness and cost
efficiency.6
In the U.K. and worldwide today, the majority
of clinicians involved in the management of co-
lorectal cancer follow their patients after the
initial surgical treatment. Although there is no
uniform pattern and there is a wide spectrum of
practise we can identify through the literature and
the so far conducted audits two general attitudes
towards follow-up of colorectal cancer: a) Inten-
sive follow-up; and b) Non-intensive follow-up.
Methods
In order to identify the optimum protocol for post-
operative follow-up of colorectal cancer a review
was performed via a Medline search of all pub-
lished studies and reports on the issue of follow-up
of colorectal cancer dated from 1975e2006. We
examined retrospective and prospective studies,
randomised controlled trials, and meta-analyses
attempting to identify the optimum follow-up
protocol (Table 3).
Intensive follow-up
Some clinicians follow up Colorectal Cancer pa-
tients after surgery very intensively: follow-up
visits are every three months the first two yearsTable 2 Summary of studies in support of follow-up of colorectal cancer in chronological order
Design Comments
Arnaud 1997 Non-randomised Large study (n ¼ 1000)
Peethambaram 1997 Non-randomised Physical examination detects recurrences in 1st year
Goldberg 1998 Non-randomised Largest study (n ¼ 1247), Dukes A excluded
Pietra 1998 RCT Frequency of visits more important than investigations
Secco 2002 RCT CEA helps with increasing survival in both high risk and low risk patients
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Meta-analysis Studies analysed Comments
Bruinvels 1994 7 non-randomised studies Intensive follow-up provides 9% survival advantage
Rosen 1998 2 RCTs, 3 non-radomised studies Intensive follow-up provides 16% survival advantage
Jeffrey 2002 5 RCTs OR 0.67 in favour of intensive follow-up
Renehan 2002 5 RCTs OR 0.81 in favour of intensive follow-up
Figueredo 2003 6 RCTs OR 0.80 in favour of intensive follow-up. The effect is
higher for studies using liver CT scan and CEAand every six months for another three years.
At every follow-up visit a variable number of
investigations may be performed: blood tests,
stool tests, tumour markers, colonoscopies, X
rays, ultrasound scans, computerised tomography
scans etc. Some surgeons have been even more
zealous in the past and tried to perform ‘‘second-
look’’ diagnostic operations7 in an attempt to de-
tect recurrence of cancer as soon as possible.
Non-intensive follow-up
The argument against intensive follow-up is that it
may not lead to true prolongation of survival but
rather lead time bias, i.e. earlier knowledge of the
existence of disease which wrongly creates the
impression of longer survival. Therefore earlier
diagnosis of disease not only fails to prolong
survival but also harms quality of life, adding
anxiety and depression resulting from earlier
knowledge of the inevitable death. This second
school of thought argues that intensive follow-up
should not be performed and again a variation of
practice occurs: some doctors see their patients
once a year and perform only a small number of
investigations. Others have been more radical and
suggested that follow-up should be abandoned
altogether and it should be left to the patients to
contact the doctor in case of symptoms.
Current guidelines and
recommendations
At the moment there is no universal follow-up
policy in the UK. This has been demonstrated in
the UK twice in the recent years: in 1987 a large
follow-up audit in Wales and South West England
showed that there is no common policy and there
was great variation in used methods.8 Ten years
later an audit by the Royal College of Surgeons in
two UK Health Regions produced exactly the
same findings.9 This is because a great variety of in-
vestigations exists and it is difficult to prove which
are the optima intervals between post-operativeexaminations. The problem however exists in
many other countries: studies among the American
Society of Colon and Rectal Surgeons10 and among
the members of the USA Society of Surgical Oncol-
ogy11 have produced conflicting results confirming
the lack of policy. A similar study in the Nether-
lands12 produced exactly the same findings and
called for European guidelines. In Europe there is
so far limited availability of national guidelines
containing detailed protocols of follow-up, one of
a few examples is Norway.13 The Norwegian follow-
up policy is relatively ‘‘intensive’’. It lasts for
4 years (as opposed to 5 which is the usual in
the U.K.) but uses bi-annual ultrasound of the
liver for four years and Carcinoembryonic Antigen
(CEA) measurement every 3 months for 2 years
and every 6 months until year four. Sigmoidoscopy
is performed by a surgeon every 6 months but it is
worth noting that the Norwegian policy allocates
to the General Practitioners the bulk of follow-
up for colonic cancer. The Norwegian protocol
also mentions specifically patient education as
one of the aims of follow-up which is expected
to make patients aware of suspicious symptoms.
In the UK, the guidelines of the National In-
stitute of Clinical Excellence accept that there
may be a benefit from follow-up but do not specify
a detailed protocol, instead they advise the agree-
ment of a follow-up protocol by each local cancer
network. Similarly, the guidelines of the Associa-
tion of Coloproctology of Great Britain and Ireland
are cautious not to specify a detailed protocol,
however it is recommended that some form of liver
imaging should be performed during the first two
years from surgery. In Scotland the guidelines of
the Scottish Intercollegiate Guidelines Network
recommend the use of CT scan and CEA in non-
specified intervals.14
Things have taken more shape across the Atlan-
tic: the American Society of Clinical Oncology have
recently adopted practice parameters15 which rec-
ommends annual CT scan of abdomen and chest for
three years with additional CT scan of the pelvis
for patients who had rectal cancer. For years 3e5
history and physical examination every 6 months
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6 months for 5 years for rectal cancer patients
who have not had radiotherapy. Colonoscopy for
metachronous tumours is recommended at 3 years
post-operatively and every 5 years thereafter.
The history of the debate: studies
against follow-up
Hulton and Hargreaves in 1989 followed a group of
114 patients with colorectal cancer and could not
find evidence that follow-up achieved prolongation
of survival.16 They suggested that more intensive
follow-up of high risk groups might be more useful.
However evaluation of their patients was mainly
clinical and there does not seem to be a standard
protocol of laboratory investigations. Furthermore
their group was small, only 100 patients were ana-
lysed, and given the complexity of the problem it
would be unlikely that any major differences
would have been discovered among subgroups.
The above two weaknesses, i.e., absence of a strict
protocol of investigations and a small sample, are
a problem in many similar studies.
Ohlsson et al. compared ‘‘intensive’’ follow-up
with no follow-up in a randomised trial.17 Their
protocol consisted of frequent examination with
clinical examination, rigid sigmoidoscopy, colono-
scopy, CT scan of the pelvis for rectal tumours
only, pulmonary X Ray, CEA and faecal haemoglo-
bin. The second group had no follow-up. Their
sample was 107 patients. Again, this sample was
also small. No CT scan or ultrasound scan of the
liver was performed on either group. Detection
of liver metastases was therefore relied upon liver
function tests and CEA measurements, a practice
with rather low sensitivity. The absence of any
liver imaging in this study may explain their finding
that no patient in either group underwent surgery
for recurrent disease of the liver. Chest X ray was
done frequently, presumably on the grounds of
low cost, but it is known that its positive yield is
less than 5%. Annual colonoscopy was employed.
Colonoscopy is at the same time expensive and in-
vasive and its value lies in detecting metachronous
tumours (0.6% risk per year) and anastomotic re-
currences (risk 1% per year for colonic tumours).
The rigorous colonoscopic surveillance in this study
resulted in the detection of only one patient with
a metachronous tumour. The authors report a trend
in difference in 5 year survival between the 2
groups (78% in the follow-up vs. 71% in the control
group) with a P value of 0.05. The weakness of this
study is the small number of patients which makes
small differences undetectable and the question iswhether statistical significance might have been
shown with a bigger sample.
A study by Lennon et al.18 used the frequent
blind determination of CEA as the primary factor
to lead to investigations and ‘‘second-look’’ sur-
gery. This policy did not improve survival of the in-
tensively treated group and actually demonstrated
a greater relative risk of death of those patients.
Although this study had a larger sample (n ¼ 216)
there were some questions raised regarding bias
from classifying as disease free some patients
with symptoms who should have been excluded
from the study. In any case this study did not ex-
amine the value of follow-up in general but only
the value of CEA as the sole factor to decide an
aggressive ‘‘investigation’’ such as a laparotomy.
Practice in recurrent colorectal cancer manage-
ment has changed considerably since this study
was designed e no surgeon would perform nowa-
days a laparotomy for detection of recurrence
since newer modalities such as PET scan could pro-
vide the answer.
McCall et al.19 have demonstrated that CEA is
the first indicator of recurrent disease in 58% of
all patients and in 80% of patients with liver metas-
tases (n ¼ 311), however their study did not in-
clude a long enough follow-up to decide if this
resulted in a survival benefit. This survival benefit
was claimed not to exist by Moertel20 in a large ret-
rospective study (n ¼ 1217). CEA was not a reliable
sole predictor of increased survival although it pro-
vided information that led to an increased number
of operations. In this case again the study was
aimed at determining the value of CEA rather
than overall follow-up.
Makela et al.21 conducted a randomised com-
parison of intensive follow-up vs. a non-intensive
one. The intensive policy was focused on detection
of liver recurrence with bi-annual US scans of the
liver and yearly CT scans. Their sample was 106 pa-
tients but it consisted of an unusually high propor-
tion of stage Dukes A cancers (26%) that are 95%
cured with surgery alone. This policy led to re-
operations in 22% of the intensive group and 14%
of the non-intensive group. There was no differ-
ence in 5 year survival. The study is small to be
conclusive, had they recruited the same number
of patients as Lennon et al. the trend might have
become significant. Furthermore, the high propor-
tion of Dukes A cancers is likely to bias the results
towards the ‘‘no benefit’’ conclusion.
A study with a larger number (n ¼ 406) of
patients was published by Cochrane in 1980.22
This is a weak publication since it is entirely retro-
spective and covers patients treated very long
ago, between 1958e1962, when many factors in
124 S. Papagrigoriadistreatment of primary and recurrent colorectal
cancer might differ.
A randomised trial by Kjeldsen et al.23 on 597
patients failed to show any benefit of intensive
follow-up. However, a closer look at this study re-
veals that the ‘‘intensive’’ follow-up group pa-
tients had six monthly clinical examinations but
did not have CT of the abdomen, ultrasound or
any other form of abdominal imaging. CEA mea-
surements were not performed either. The main
means of investigations were clinical examination,
Colonoscopy, haematology and biochemistry tests,
all of which do not have the potential of early
detection of liver recurrence. As a result of these
deficiencies the conclusions of this trial are viewed
by the present author with scepticism.
The strongest study against intensive follow-up
came from Australia in 1998. Schoemaker et al.24
randomised 325 patients and found that annual co-
lonoscopy, CT scan and Chest X ray increased oper-
ations but not overall survival. The second group of
the study contained follow-up with physical exam-
ination, CEA and liver function tests, blood count,
faecal occult blood test and colonoscopy at 5 years
only. Chest X ray was not particularly useful since
only 3 patients were found to have isolated lung
metastases which were resected, however only
one of them achieved long term survival. Although
they detected 14 patients with liver metastases
they were able to resect them only in 4 cases. No
cryotherapy was applied.
The history of the debate: studies
supporting follow-up
Arnaud et al. published in 1997 a prospective trial
(intensive follow-up vs. no follow-up) with a sample
of 1000 patients. Surgical resection of recurrent
tumors was performed in 37% of the intensive group
patients (curative resection in 15%) and in 9%
(curative resection in 1.5%) of the no follow-up
group patients (P < 0.001). 5-year survival after re-
currence in the intensive group was 11.5% versus 1%
in the no follow-up group (P < 0.01).25 The authors
conclude that follow-up has better survival than if
the patients are left to make unscheduled visits
in case of symptoms. The same study but with
800 patients and the same conclusions had been
published as Bergamaschi and Arnaud in 1996.26
A randomized trial from Italy by Pietra et al. on
207 patients27 showed that the difference in the
frequency of the follow-up visits rather than
the kind of investigations made a difference in the
detection and the outcome of local recurrence.
Patients were randomized in a group A seen twicethe first year and yearly afterwards and a Group B
seen every 3 months the first 2 years and every
6 months for the next 3 years. Patients in the fre-
quent visits group had a 5 year survival of 73% com-
pared to that of the infrequent visit group which
was 58% (P < 0.02). Furthermore there seemed to
be a greater benefit for patients with rectal cancer
since in Group A only one patient was possible to
have a curative resection of local recurrence as
opposed to 11 patients with curative resection of
rectal recurrence in Group B. This study raises
the question whether we should establish different
follow-up patterns for colonic and rectal cancer
respectively since there is a different pattern of
recurrence with local recurrence being more fre-
quent in rectal cancer. No further evidence exists
regarding this question.
A retrospective multi- institutional cohort study
by Goldberg28 in 1998 examined 1247 patients with
resected colorectal cancer excluding Dukes A.
Of those patients 548 had a second operation for
resection of recurrence and the overall results
were good with a median 5 year survival of 50%.
The majority of those operations were prompted
by findings on follow-up of asymptomatic patients
and a raised CEA. The authors conclude that ag-
gressive second time surgery is worth pursuing on
colorectal cancer patients. This study has a large
sample but it is not randomized.
Howell et al. looked specifically into liver
ultrasound scan and found that frequent liver
imaging can detect liver metastases from colorec-
tal cancer at an asymptomatic stage.29
A prospective non-randomised study on 98
patients with B and C only stage cancers30 found
that most recurrences were detected by symptoms
in the first year post surgery but not by screening
asymptomatic patients after the 2nd year post-
surgery. The message of this study sounds rather
confusing but it may indicate a larger number of
advanced or aggressive tumours in their material
that recurred earlier than usual.
Secco et al. attempted to stratify patients
according to high or low risk for recurrence after
curative resection.31 They randomised both high
risk and low risk patients and found that there
was a survival benefit for both groups if they
were under intensive follow-up. There did not
seem to be any difference in financial costs.
The resolution of the debate:
meta-analyses support follow-up
The small numbers of patients in all the previously
mentioned studies is an indication for performing
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far performed and all five of them have concluded
in favour of intensive follow-up.
A meta-analysis by Bruinvels et al.32 found
a slight benefit in survival of patients with an in-
tensive follow-up policy. However this publication
points out that there are so many follow-up strat-
egies that comparison and statistical conclusions
are difficult.
A meta-analysis by Rosen et al. found that the
cumulative five-year survival was 1.16 times higher
in the intensively followed group (P ¼ 0.003). Two
and one-half times more curative re-resections
were performed for recurrent cancer in those
patients undergoing intensive follow-up (P ¼ 0.0001)
. Those patients in the intensive follow-up group
with a recurrence had a 3.62-times higher survival
rate than the control (P ¼ 0.0004).33
A Cochrane meta-analysis by Jeffrey et al. in
2002 confirmed a survival benefit for the inten-
sively followed patient group with a reduced
mortality risk (OR 0.67, or 0.53e0.84 at 95%
confidence intervals) but those authors were un-
able to conclude from their analysis which tests
were more advantageous. They were also unable
to find and analyze adequate data on quality of life
or cost-effectiveness.34
A meta-analysis by Renehan et al.35 found that
intensive follow-up was associated with earlier
detection of all metastatic disease (intraluminal,
local and distant) and decreased mortality (com-
bined risk ratio 0.81, 95% confidence interval
0.70 to 0.94, P ¼ 0.007). It seems that frequent
CT scan and CEA measurement were the main
determinants of increased survival since the mor-
tality risk was even lower (risk ratio 0.73, 0.60 to
0.89, P ¼ 0.002) on the four studies that used
those modalities more intensively. This meta-
analysis therefore concluded that intensive follow-
up should be practiced and it should rely mainly on
frequent CT scans and CEA measurements.
The most recent systematic review and
meta-analysis by Figueredo et al. analyzed six
randomized trials (the only one that included the
randomized trial by Secco et al.) and confirmed
a reduced mortality risk for those patients who are
on intensive follow-up (OR 0.80, 0.70e0.91 at 95%
confidence intervals).36
Cost issues
A main reason for the debate is the cost: follow-up
of colorectal cancer is potentially expensive and
since the disease is so common it can consume
a great amount of resources of the healthsystems.37 It has also been proven very difficult to
establish generally acceptable guidelines for
a cost-efficient follow-up policy, and views in
favour of abandoning any follow-up policy all
together have started circulating in managerial
circles and among NHS ‘‘decision makers’’.38 The
NHS Executive publications present the evidence
in a light that rather leads the reader to conclude
that follow-up is not efficient and should be aban-
doned.39,40 However these publications have not
taken into account all the existing, more recent,
evidence in favour of intensive follow-up. The
amount of money that can be spent on follow-
up schemes varies tremendously: according to a
study11 there can be a 28-fold difference in
expenses depending on the physician’s choice of re-
gime. A cost analysis comparing physical examina-
tion with CEA, Chest X Ray and colonoscopy found
that CEA was the most cost-efficient method with
a ‘‘cost per recurrence’’ of $5696. Although one
would think that physical examination would be
the cheapest method, it could not detect almost
any recurrences so the estimated ‘‘cost per recur-
rence’’ was $418,615! A recent cost -effectiveness
study by Renehan et al. found the cost of intensive
follow-up to be £3402 per year of life which is
considered a low figure indicating good cost-
efficiency. They conclude that there is no rationale
to abandon follow-up on the basis of cost.41
Quality of life issues
Almost all the above mentioned studies use two
criteria to assess the value of follow-up: prolonga-
tion of survival and cost-efficiency. Quality of Life
(QoL) almost seems to be taken for granted by
most medical authors, or perhaps is considered
appropriate for other health professionals to deal
with it, since only 3% of trials reported in surgical
journals deal even partly with QoL issues.42 Many
of colorectal cancer patients, with or without re-
currence, are known to suffer from a number of
problems that do not have to do with survival:
pain, skin and other stoma problems, side effects
of opiates, wound problems, sexual dysfunction
after pelvic surgery, fatigue, anxiety and depres-
sion.43 Detection of those problems has not been
considered part of the follow-up since it is as-
sumed that patients will report those symptoms
and seek help if they appear. However it is known
that these problems are usually under-reported
and special methods and measurement scales
have been developed to uncover them.44,45
It is known that patients perceive and priori-
tise health risks differently than clinicians and
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perseded by fears of disability, financial and social
consequences.46 Even predictions about how good
their quality of life is are often inaccurate and
questionnaires to discover ‘‘trade offs’’ between
quantity and quality of life have been developed
for this purpose.47 While health professionals are
mainly interested in increased survival and cost ef-
ficiency when designing cancer follow-up, what are
cancer patients interested in?
A study from The Netherlands by Stiggelbout
et al. in the literature investigated the views of
colorectal cancer patients48 found that patients’
priorities were different. Patients seemed to
seek in follow-up not only a prolongation of sur-
vival but also psychological support and a constant
communication link with their doctors. They did
not mind being submitted to investigations, even
invasive ones, and the anxiety caused by them
was not enough to discourage them. Finally, they
wanted to have the follow-up even if they were
told that this would not prolong survival.
A study in the UK by the present author49
found that although follow-up visits caused tem-
porary anxiety in up to one third of the patients,
this effect was replaced with reassurance, opti-
mism and feeling of well being in case of nega-
tive results. The majority (78%) of patients
valued follow-up and stated they would like to
know about the presence of recurrence even if
this would not increase survival, in order to
deal with practical and family problems or simply
to prepare for death. Sixty four percent of pa-
tients in that study would like to know what
are the symptoms of recurrence in order to alert
themselves earlier. A previous study of ours indi-
cated that 56% of the General Practitioners
might agree to take an active role in the fol-
low-up of colorectal cancer in replacement of
the hospital50 provided they would be given
guidelines and fast access of referral to specialist
hospital services. However only 27% of the pa-
tients would agree to be followed up by their
GP for colorectal cancer. Half of the patients
would strongly disagree with any attempt to in-
terrupt their follow-up process.
In view of the above findings questions arise
whether any attempt from clinicians to ‘‘protect’’
patients from ‘‘unnecessary’’ knowledge of the
presence of recurrence might appear unjustified
and even paternalistic. The concept of ‘‘patient
partnership’’51,52 which has recently emerged as
a major issue in medical decision making and is
supposed to replace old fashioned ‘‘medical pater-
nalism’’ should not leave out the follow-up of the
second commonest cancer in the UK.Questions which remain unanswered
Most of the so far studies have treated the
population of colorectal cancer patients as a homo-
geneous group. Could it be the case that we might
find more effective a two tier follow-up: a more
intensive protocol for tumours which have aggres-
sive histological characteristics and have presented
as T2 and above versus a less intensive protocol for
less aggressive T1 tumours? The study which would
look into this issue remains to be designed.
Will the evolution and increasing availability of
PET scan make the detection of micro-metastases
easier at an earlier stage? This would result in
avoidance of futile surgery and possibly more wide-
spread use of adjuvant and neo-adjuvant treatments.
Patients’ expectations from follow-up visits are
variable, difficult to meet and often depend on
personal and cultural factors.53,54 Can those ex-
pectations be always met in a hospital environ-
ment or should we try to transfer part of cancer
follow-up in the community?55,56 In that case it
should not be attempted as a ‘‘discharge back to
primary care’’ but as shared care based on guide-
lines. Research on similar attempts has been
made on inflammatory bowel disease, breast can-
cer etc. with results that were similar to those of
hospital based follow-up.57e60
At present it appears that some variability in
follow-up policies of colorectal cancer will remain
and will depend on local circumstances and individ-
ual features of various health services, however it
should always remain protocol-based and pursue the
aim of early detection of cancer recurrence.
Although there is a convincing conclusion to the
twenty year old debate about the benefit of
follow-up another debate is now forming, that of
the optimal and cost efficient protocol of investi-
gations. CEA appears to be the main consensus
point, and the debate about frequent liver imaging
with CT scan seems to be coming to a conclusion as
well since the publishing of the 2005 guidelines of
the American Society of Clinical Oncology. The
evolution of imaging technologies may give in the
near future more cost-efficient options.
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